Based on Phase 2 clinical trial data published in the New England Journal of Medicine (2023), retatrutide shares a side-effect profile broadly consistent with other GLP-1 receptor agonist class medicines, though the addition of glucagon receptor agonism may introduce some distinct effects
The phase 2 obesity trial and MASLD substudy included 1 mg, 4 mg, 8 mg, and 12 mg once-weekly subcutaneous retatrutide [4], [6]
I then turned 65 yrs old and that is the age I had to switch to Tricare for life, with Medicare A and B which now TFL doesnt cover my Zepbound anymore
GLP-1 Medications 2025: Cost, Coverage, and Who Should Consider Them If you're researching GLP-1 medications like Ozempic, Wegovy, Mounjaro, or Zepbound, you probably have two main questions: How much will this cost me